| 蔡立文,张彬,王欣俞.药学监护路径管理对急性冠状动脉综合征患者用药使用率干预价值研究[J].中国药事,2023,(9):1074-1082 |
| 药学监护路径管理对急性冠状动脉综合征患者用药使用率干预价值研究 |
| Study on Intervention Value of Pharmaceutical Care Pathway Management on Drug Use Rate in Patients with Acute Coronary Syndrome |
| 投稿时间：2022-05-07 |
| DOI：10.16153/j.1002-7777.2023.09.012 |
| 中文关键词: 药学监护路径 急性冠状动脉综合征 药物使用率 有效性 安全性 |
| 英文关键词: pharmaceutical care pathway acute coronary syndrome drug use rate eff ectiveness safety |
| 基金项目:2019年度河北省医学科学研究课题（编号 20191063 ） |
|
| 摘要点击次数: 489 |
| 全文下载次数: 279 |
| 中文摘要: |
| 目的：探究药学监护路径管理对急性冠状动脉综合征（ACS）患者用药使用率干预价值。方法： 选取河北燕达医院2020年1月至2021年12月收治的住院ACS患者124例作为研究对象，其中2020年1-12月期间收治62例患者为对照组，实施常规药物治疗管理，2021年1-12月期间收治62例患者为实验组，实施药学监护路径管理，分析两组患者药物使用率、治疗目标达标率、不良反应发生率以及用药常见问题。结果：实验组在实施药学监护路径管理后，药物治疗期间适应证、有效性、安全性方面相关问题数量明显低于对照组（P＜0.05）；实验组患者药物知识知晓满分率高于对照组（P＜0.05）；实验组患者不良反应发生率低于对照组（P＜0.05）；实验组患者β-受体阻滞剂、血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂（ACEI/ARB）二级预防用药使用率高于对照组（P＜0.05）；实验组患者体质量指数、血压、静息心率控制达标率高于对照组（P＜0.05），血压、静息心率水平低于对照组（P＜0.05）；实验组患者6 个月时再入院率低于对照组（P＜0.05）。结论：对ACS患者采用药学监护路径管理可有效减少患者用药问题，提高药物治疗安全性及有效性，提高患者二级预防用药使用率，达到更好的药物控制效果。 |
| 英文摘要: |
| Objective: To explore the intervention value of pharmaceutical care pathway management on medication utilization rate in patients with acute coronary syndrome (ACS). Method: A total of 124 inpatient ACS patients admitted to our hospital from January 2020 to December 2021 were selected as the research subjects, of which 62 patients were admitted from January 2020 to December 2020 as the control group, and routine drug treatment management was implemented in 2021. From January to December 2021, 62 patients were admitted as the experimental group, and the management of pharmaceutical care pathways was implemented. The drug usage rate, treatment target compliance rate, incidence of adverse reactions, and common medication problems were analyzed in the two groups. Results: After the implementation of pharmaceutical care pathway management, the number of problems related to indications, effi cacy and safety during drug treatment in the experimental group was signifi cantly lower than that in the control group (P＜0.05); the full score rate of drug knowledge awareness in the experimental group was higher than that in the control group (P＜0.05); the use rate of secondary preventive drugs such as β-receptor blockers, angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) was higher than that of the control group (P＜0.05); the use rate of secondary preventive drugs in the experimental group was higher than that in the control group (P＜0.05). Lower than the control group (P＜0.05); the readmission rate of patients in the experimental group at 6 months was lower than that in the control group (P＜0.05). Conclusion: The use of pharmaceutical care pathway management for patients with ACS can eff ectively reduce the problem of drug use, improve the safety and eff ectiveness of drug treatment, increase the utilization rate of secondary prevention drugs, and achieve better drug control eff ect. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |